PHILADELPHIA, PA & SAN FRANCISCO, CA — Dispatch Bio announced that it will present new data on its investigational cancer therapy, DISP-10, at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, scheduled for November 5–9 in National Harbor, Maryland.
The company will share two posters highlighting its work to combine CAR T cell therapy with a tumor-specific viral vector to create a potential universal treatment for epithelial tumors — the most common form of solid cancers.
The first presentation, titled “DISP-10 is a novel CAR T and tumor-specific virus combination undergoing clinical development that is designed for use as a universal treatment for epithelial tumors,” will be presented by Senior Scientist Lisa Cucolo, Ph.D., on Friday, November 7 (Abstract 393, Cellular Therapies category).
A second presentation, “Combination of a tumor-specific virus and CAR T to specifically and universally target tumors of epithelial origin and overcome challenges of the tumor microenvironment,” will be delivered by Raymond Liu, Ph.D., Co-Founder and Head of Synthetic Biology at Dispatch, on Saturday, November 8 (Abstract 394, Cellular Therapies category).
Founded in 2022, Dispatch Bio is developing a new class of therapies that merge the precision of immunotherapy with the targeting power of engineered viral vectors. The company’s proprietary Flare platform aims to overcome barriers associated with solid tumors by enabling the immune system to identify and destroy cancer cells across multiple epithelial tumor types.
With operations in both Philadelphia and San Francisco, Dispatch Bio brings together cross-disciplinary expertise in synthetic biology, immunology, and oncology to advance next-generation cancer treatments designed to broaden access and improve patient outcomes.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.